Why Isn’t Paper the Same as Electronic?

/, CGMP, FDA Inspections, Medical Devices/Why Isn’t Paper the Same as Electronic?

Why Isn’t Paper the Same as Electronic?

By | 2018-08-29T16:51:54+00:00 August 29th, 2018|Biopharma / Pharma, CGMP, FDA Inspections, Medical Devices|

Most of us feel comfortable with paper records. We can see them, feel them, touch them (apologies to Peter Townshend).

We like to think they’re the same as electronic records. But we hear rumblings from GMP inspections that FDA doesn’t always share that view.

What are the 2 keys?

  1. Content
  2. Meaning

Let’s explore a simplified, hypothetical example to give you ideas on what to look for, the kinds of tactics you can use, and how to communicate effectively with your auditee.

Hypothetical Flow Cytometry Example

You’re auditing Acme Labs, a central lab performing flow cytometry for one of your company’s studies. Your company will use the results to support safety claims.

Do Your Homework

Before the Audit

  • Review the instrument manufacturer’s manuals on-line
  • Identify the outputs you should see
  • Note potential pitfalls

Get Your Personalized CFR Trend Report. Just tell us the top 5 companies that you are interested in, and we’ll send you a list of the trending CFR Citations for that group.

You identify 4 different files created by the flow cytometer:

  1. Experiment
  2. Data
  3. Statistics
  4. Instrument settings

You note that the manufacturer recommends storing files on the instrument hard drive and moving them to other locations “later.” Hmmm. Wonder what that will look like?

Conduct the audit

The cytometry lab manager explains their SOPs require printing the test results, reviewing the printouts, and identifying the printout as the raw data.

Your job?

Work with the lab to discover if the paper printouts are equivalent in content and meaning to the electronic records.

Start by looking at the most recent notebook of the printouts. You note they are all in black and white, including the plots. In discussions with lab personnel, you confirm the colors displayed by the flow cytometer are very important and play a role in interpreting the results and conducting a meaningful review.

Select a sample of printouts. Move back to the instrument and ask the operator to show you the experiment, data, statistics, and instrument settings files for your sample. (If for some reason, they can’t, try a different angle. Ask to see the files for the most recent run.) You and the operator confirm the contents of the settings file are not included in the printout.

Discussion confirms the lab follows the manufacturer’s recommendation not to save files directly to external storage. However, the lab only saves the settings files locally on the instrument hard drive and never moves them to external storage. The instrument automatically deletes older settings files as space on the hard drive is used up.

You have collaborated with the lab to help them understand that paper printouts are not equivalent in content (instrument setting files are missing) or meaning (color is important).

Write the finding(s). “Acme Lab failed to maintain complete and accurate laboratory data generated in the course of establishing the safety of the investigational product. Acme’s SOPs did not include instructions for the retention of electronic raw data, and instrument settings files have been deleted. Printed flow cytometer results did not include all required information for adequate review. For example, instrument settings were not included, and color plots were printed in black and white.”

What about the predicate rule?

GLP Study

Consider starting with 58.81 Standard operating procedures and 58.190 Storage and retrieval of records and data. See also the Colorado Histo-Prep Warning Letter for a recent example, including citations against the Quality Assurance Unit.

GCP Study

Current FDA podium-speak is that the Centers for Medicare and Medicaid Services (CMS) are responsible for clinical labs. That does not absolve sponsors or clinical labs of the responsibility to ensure the quality and integrity of clinical trial lab data.

Consider 312.22 General principles of the IND submission. This requires assurance of subject safety and that the quality of the scientific evaluation be “adequate to permit an evaluation of the drug’s effectiveness and safety” and “yield data capable of meeting statutory standards for marketing approval.”

Your Takeaway

When an auditee tells you they use paper records instead of electronic records…

  1. Look for differences in content and meaning
  2. Work with the auditee to understand the differences you find

Get Your Personalized CFR Trend Report. Just tell us the top 5 companies that you are interested in, and we’ll send you a list of the trending CFR Citations for that group.

Learn more about how FDAzilla can help you achieve your quality and inspection preparation goals: get 483sInspector ProfilesEnforcement Analytics, and GMP Regulatory Intelligence. Contact us if you ever have questions at sales@fdazilla.com.

Leave A Comment